<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345916</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1009-PR-0050</org_study_id>
    <secondary_id>2010-023281-47</secondary_id>
    <nct_id>NCT01345916</nct_id>
  </id_info>
  <brief_title>Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients</brief_title>
  <acronym>Neptune</acronym>
  <official_title>A Phase 3,8-week Clinical Trial to Test the Efficacy of CHF1535 Via NEXT DPI® Versus Same Dose of CHF1535 pMDI and Beclomethasone DPI 100µg on PEF in Adult Asthmatic Patients After 1 Month of Treatment With FOSTER®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that CHF 1535 NEXT DPI® is non-inferior to the
      corresponding dose of CHF 1535 pMDI and superior to marketed beclomethasone DPI 100 µg in
      terms of average pre-dose morning Peak Expiratory Flow (PEF) in asthmatic adult patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to demonstrate that CHF 1535 NEXT DPI® (beclomethasone dipropionate
      + formoterol fumarate 100/6 μg), 1 inhalation twice daily, is non-inferior to the
      corresponding dose of CHF 1535 pMDI in terms of pulmonary function test (change from baseline
      to the entire treatment period in average pre-dose morning PEF) in asthmatic adult patients ≥
      18 years under treatment with fixed dose combination of Foster® (beclomethasone dipropionate
      + formoterol fumarate 100 / 6 μg) 1 inhalation bid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to the entire treatment period in average pre-dose morning Peak Expiratory Flow.</measure>
    <time_frame>at 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dose morning FEV1 (Forced Expiratory Volume in one second);</measure>
    <time_frame>at 2, 4, 6 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose morning FVC (Force Vital Capacity) ;</measure>
    <time_frame>at 2, 4, 6 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ (Asthma Control Questionnaire) score ;</measure>
    <time_frame>at eight weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-dose evening PEF ;</measure>
    <time_frame>at 2, 4, 6 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily PEF variability ;</measure>
    <time_frame>at 2, 4, 6 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of rescue medication ;</measure>
    <time_frame>at 2, 4, 6 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of rescue use-free days</measure>
    <time_frame>at 2, 4, 6 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-dose morning PEF ;</measure>
    <time_frame>at 2, 4, 6 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">932</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 1535 100/6 NEXT Dry Powder Inhaler®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF1535 100/6 NEXT DPI® 1 inhalation bis in day (b.i.d) (daily dose BDP 200/FF 12 µg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF1535 100/6 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF1535 100/6 pressurisedMeterDoseInhaler 1 inhalation b.i.d (total daily dose BDP 200/FF 12 µg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>beclomethasone dipropionate DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beclomethasone dipropionate 100 µg DPI, 1 inhalation b.i.d (total daily dose BDP 200 µg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 100/6 NEXT DPI® 2 months</intervention_name>
    <description>CHF 1535 100/6 NEXT DPI® 2 months</description>
    <arm_group_label>CHF 1535 100/6 NEXT Dry Powder Inhaler®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 100/6 pMDI 2 months</intervention_name>
    <description>CHF 1535 100/6 pMDI 2 months</description>
    <arm_group_label>CHF1535 100/6 pMDI</arm_group_label>
    <other_name>Foster®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP DPI 2 months</intervention_name>
    <description>BDP DPI 2 months</description>
    <arm_group_label>beclomethasone dipropionate DPI</arm_group_label>
    <other_name>Clenil® Pulvinal®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female adults (≥18 years old).

          2. Reversibility test defined as ΔFEV1 ≥ 12% and ≥ 200 mL .

          3. FEV1 &gt; 80% of the predicted values .

          4. Asthma Control Questionnaire score &lt; 1.25.

          5. Asthmatic patients

          6. Non- or ex-smokers

        Exclusion Criteria:

          1. History of near fatal asthma.

          2. COPD patients

          3. Asthma exacerbation within 1 month prior to the screening visit or asthma exacerbation
             during the run-in period.

          4. Lower respiratory tract infection within 1 month prior Visit1 (V1).

          5. History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency.

          6. Diagnosis of restrictive lung disease.

          7. Patients treated with oral or parenteral corticosteroids in the previous 2 months
             before V1

          8. Intolerance or contra-indication to treatment with beta 2-agonists and/or inhaled
             corticosteroids or allergy to any component of the study treatments.

          9. Significant medical history of and/or treatments

         10. Active cancer or a history of cancer .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank KANNIESS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemeinschaftspraxis Reinfeld - Raiffeisenpassage 15 - D-23858 Reinfeld - Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSPZOZ Uniwersytecki Szpital Kliniczny</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023281-47</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial. Pulm Pharmacol Ther. 2015 Feb;30:121-7. doi: 10.1016/j.pupt.2014.07.006. Epub 2014 Aug 1.</citation>
    <PMID>25088067</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

